On Wednesday 15th January 2020, US president Donald Trump and Chinese vice-premier Liu He signed an economic and trade agreement which Mr Trump described as “the biggest deal anybody has even seen”. The deal promises to be the first phase of a larger new trade agreement between the US and China, signifying a de-escalation in their trade war – at least for now. Intellectual property (IP) was one of the main points of contention during the trade talks and thus it is perhaps unsurprising that IP matters are addressed in the first chapter. Of particular interest to those in the pharmaceutical sector will be Sections C and D of Chapter 1, which outline China’s commitment to improving protection and enforcement of pharmaceutical related patent rights. Sceptics will argue that these provisions simply represent a long overdue pledge by China to align its patent system with the US and other Western states, with no guarantee that they will actually implement or enforce the provisions of the agreement. However, in my view the deal appears to represent China’s willingness to do more to protect pharmaceutical patent rights and contains provisions that (if properly implemented and enforced) could significantly increase the value of drug related patents in China.
Insights: January 2020
The EPO says they’d be ready to get going with Unitary Patents later this year. Has anyone else spotted the (Br)elephant in the room? According to a press release published by the European Patent Office (EPO) on 10th January 2020, the EPO president António Campinos and his team have recently met with the Chair of the EPO Unitary Patent (UP) Select Committee and members of the Unified Patent Court (UPC) Preparatory Committee from the EU member states. The main item on the agenda for them was a discussion of the most recent developments concerning the implementation of UP and UPC (the so called Unitary Patent package, which we have talked about here).
As of 3 January 2020, the Hague System is in force in Israel, Samoa and Vietnam. This means that applicants can now seek design protection in these countries in a Hague System application, and that applicants based in these three countries can now take advantage of the benefits offered by seeking design protection through the Hague System.
Whether you like it or not, the UK is a windy place. It is therefore not surprising that wind accounted for more than 50% of the electricity generated from renewable energy sources in 2019. Modern energy generation wind turbines can come in many forms, in this blog I will discuss vertical axis wind turbines (VAWTs) which are becoming a larger part of the wind renewable energy market.
A recent decision of the General Court demonstrates that a trade mark may be refused if it is considered to be contrary to public policy in one or more of the EU Member States, even though the grounds of refusal might not apply throughout the EU.